PSORAS
MCID: PSR001
MIFTS: 64

Psoriatic Arthritis (PSORAS) malady

Categories: Genetic diseases, Skin diseases

Aliases & Classifications for Psoriatic Arthritis

Aliases & Descriptions for Psoriatic Arthritis:

Name: Psoriatic Arthritis 54 12 25 66 29 41 14
Psoriatic Arthropathy 12 25 66
Arthropathic Psoriasis 12 25
Arthritis, Psoriatic 42 69
Psoriatic Arthritis, Susceptibility to 13
Psoriasis Arthropathica 66
Arthritis Psoriatica 12
Arthritic Psoriasis 66
Arthritis Psoriatic 52
Psoras 66

Classifications:



External Ids:

OMIM 54 607507
Disease Ontology 12 DOID:9008
ICD10 33 L40.5 L40.50
ICD9CM 35 696.0
MeSH 42 D015535
NCIt 47 C61277
UMLS 69 C0003872

Summaries for Psoriatic Arthritis

MedlinePlus : 41 psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. you usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. some people with psoriasis have psoriatic arthritis. it causes pain, stiffness, and swelling of the joints. it is often mild, but can sometimes be serious and affect many joints. the joint and skin problems don't always happen at the same time. your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. there is no cure, but medicines can help control inflammation and pain. in rare cases, you might need surgery to repair or replace damaged joints.

MalaCards based summary : Psoriatic Arthritis, also known as psoriatic arthropathy, is related to hepatitis and collagenous colitis, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Adalimumab and Certolizumab pegol have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and hematopoietic system

Disease Ontology : 12 A syndrome that occurs in humans with psoriasis who also experience symptoms similar to arthritis.

Genetics Home Reference : 25 Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.

OMIM : 54 Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong... (607507) more...

UniProtKB/Swiss-Prot : 66 Psoriatic arthritis: An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

Wikipedia : 71 Psoriatic arthritis is a long-term inflammatory arthritis that occurs in people affected by the... more...

Related Diseases for Psoriatic Arthritis

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 266)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.4 HLA-C HLA-DRB1 TNF
2 collagenous colitis 29.8 CRP IL1B NOD2 S100A12 TNF
3 neuropathy 29.8 CRP IL1B TNF
4 cryptococcosis 29.8 HLA-DRB1 TNF TNFRSF1B
5 dermatitis herpetiformis 29.8 MMP3 TNF TNFRSF1B
6 rheumatoid arthritis 29.3 COMP CRP HLA-DRB1 IL1B LTA MMP3
7 celiac disease 28.8 CRP MMP3 NOD2 TNF TNFRSF11B TNFRSF1A
8 spondyloarthropathy 1 11.8
9 arthritis 11.6
10 psoriasis 11.6
11 psoriatic juvenile idiopathic arthritis 11.3
12 intussusception 10.4 IL1B TNF
13 spondylitis 10.4
14 swine influenza 10.3 CRP HLA-DRB1 TNF
15 cataract 10.3 CRP IL1B TNF
16 pulmonary hemosiderosis 10.3 HLA-DRB1 LTA TNF
17 amyotrophic lateral sclerosis type 14 10.3 IL1B NOD2 TNF
18 parkinson disease 11 10.3 IL1B NOD2 TNF
19 benign neonatal seizures 10.3 CRP IL1B TNF
20 meier-gorlin syndrome 3 10.3 IL1B NOD2 TNF
21 functional gastric disease 10.3 CRP NOD2 TNF
22 plummer's disease 10.3 CRP HLA-DRB1 TNF
23 urticaria 10.3 CRP IL1B TNF
24 nasopharyngitis 10.3 IL1B LTA TNF
25 motility-related diarrhea 10.3 HLA-DRB1 IL1B TNF
26 atrophy of prostate 10.3 CRP IL1B TNF
27 kernicterus due to isoimmunization 10.3 HLA-C HLA-DRB1 LTA TNF
28 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.3 IL1B SELE TNF
29 hidradenitis 10.3 CRP HLA-DRB1 IL1B
30 right ventricle hypoplasia 10.3 HLA-DRB1 SELE TNF
31 dermatomycosis 10.3 CRP SELE TNF
32 autosomal recessive type iv ehlers-danlos syndrome 10.3 IL1B TNF TNFSF11
33 blepharochalasis 10.3 CRP IL1B TNF
34 immunoglobulin g deficiency 10.3 HLA-DRB1 IL1B TNF
35 acute cholangitis 10.3 HLA-C HLA-DRB1 TNF
36 choroiditis 10.3 CRP IL1B TNF
37 carotenemia 10.3 CRP MMP3 TNF
38 retinal vascular occlusion 10.3 IL1B LTA TNF
39 infancy electroclinical syndrome 10.3 CRP IL1B TNF
40 rift valley fever 10.3 CRP IL1B LTA TNF
41 migraine with aura 10.3 IL1B SELE TNF
42 newcastle disease 10.3 NOD2 TNF TNFRSF1B
43 unilateral hypoactive labyrinth 10.3 CRP IL1B TNF
44 pyelonephritis 10.3 CRP IL1B TNF
45 human immunodeficiency virus infectious disease 10.3 CRP HLA-DRB1 IL1B TNF
46 colon adenocarcinoma 10.3 CRP IL1B TNF
47 blue toe syndrome 10.2 IL1B LTA TNF
48 stiff-person syndrome 10.2 CRP HLA-DRB1 PTPN22
49 orbital osteomyelitis 10.2 HLA-C MMP3 TNF TNFSF11
50 anterior corneal pigmentation 10.2 HLA-C HLA-DRB1 PTPN22

Graphical network of the top 20 diseases related to Psoriatic Arthritis:



Diseases related to Psoriatic Arthritis

Symptoms & Phenotypes for Psoriatic Arthritis

Clinical features from OMIM:

607507

UMLS symptoms related to Psoriatic Arthritis:


back pain, muscle cramp, sciatica

GenomeRNAi Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.16 HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.16 MICA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.16 HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.16 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.16 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.16 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.16 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.16 SELE
9 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.16 HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.16 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.16 NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.16 NOD2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.16 HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.16 SELE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.16 SELE MICA NOD2 HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.16 NOD2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.16 HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.16 NOD2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.16 HLA-C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.16 NOD2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.16 SELE
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.16 NOD2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.16 MICA
24 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.16 HLA-C
25 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.16 MICA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.16 HLA-C
27 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.16 HLA-C
28 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.16 MICA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.16 HLA-C
30 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TNFRSF1B IL1B LTA NOD2 TNF TNFRSF11B
31 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 TNFRSF1B IL1B LTA NOD2 TNF TNFRSF11B

MGI Mouse Phenotypes related to Psoriatic Arthritis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 IL13 IL1B LTA MMP3 NOD2 PTPN22
2 growth/size/body region MP:0005378 10.21 COMP IL13 LTA NOD2 PTPN22 SELE
3 homeostasis/metabolism MP:0005376 10.21 CRP IL13 IL1B LTA MMP3 NOD2
4 cardiovascular system MP:0005385 10.2 LTA PTPN22 SELE TNF TNFRSF11B TNFRSF1A
5 immune system MP:0005387 10.2 TNFRSF1B TNFSF11 TNIP1 COMP CRP IL13
6 integument MP:0010771 9.86 TNFRSF1B TNFSF11 TNIP1 IL13 IL1B SELE
7 liver/biliary system MP:0005370 9.7 LTA PTPN22 SELE TNF TNFRSF1A TNFRSF1B
8 respiratory system MP:0005388 9.56 TNF TNFRSF1A TNFRSF1B TNFSF11 IL13 LTA
9 skeleton MP:0005390 9.36 COMP IL13 IL1B LTA MMP3 NOD2

Drugs & Therapeutics for Psoriatic Arthritis

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
2
Certolizumab pegol Approved Phase 4,Phase 3,Phase 1 428863-50-7
3
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2 185243-69-0
4
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
5
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2 624-49-7 637568 5271565
6
Zinc Approved Phase 4 7440-66-6 32051 23994
7
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
8
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
9
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 608141-41-9 11561674
10
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
11
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
13
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
14 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
15 Adrenocorticotropic Hormone Phase 4
16 beta-endorphin Phase 4
17 Hormone Antagonists Phase 4,Phase 1,Phase 2
18 Hormones Phase 4,Phase 1,Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Phase 2
20 Melanocyte-Stimulating Hormones Phase 4
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
22 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
31 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
32 Vaccines Phase 4,Phase 2
33 Calcium, Dietary Phase 4
34 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
36 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
37 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
38 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
39 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
40 glucocorticoids Phase 4,Phase 1,Phase 2
41 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
42 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
45 triamcinolone acetonide Phase 4
46 Triamcinolone diacetate Phase 4
47 Triamcinolone hexacetonide Phase 4
48 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
49 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
50
Ustekinumab Approved, Investigational Phase 3,Phase 2 815610-63-0

Interventional clinical trials:

(show top 50) (show all 287)
id Name Status NCT ID Phase
1 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4
3 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
4 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Unknown status NCT00573651 Phase 4
5 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis Unknown status NCT01088165 Phase 4
6 A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics Completed NCT02470481 Phase 4
7 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
8 Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis Completed NCT00245960 Phase 4
9 HUmira in Psoriatic Arthritis Completed NCT01465438 Phase 4
10 REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) Completed NCT00127842 Phase 4
11 Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis Completed NCT00432406 Phase 4
12 An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Completed NCT00760669 Phase 4
13 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4
14 Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain Completed NCT00195377 Phase 4
15 National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study Completed NCT01123265 Phase 4
16 Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis Completed NCT00161655 Phase 4
17 TNFalfa Blocking Treatment of Spondylarthropathies Completed NCT00133315 Phase 4
18 Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Completed NCT01604629 Phase 4
19 Centocor Microarray Study of Patients Completed NCT00462072 Phase 4
20 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet Completed NCT00735787 Phase 4
21 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4
22 A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation Recruiting NCT02814175 Phase 4
23 Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo Recruiting NCT02798211 Phase 4
24 Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis Recruiting NCT02437461 Phase 4
25 The NOR-SWITCH Study Active, not recruiting NCT02148640 Phase 4
26 A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis Not yet recruiting NCT03151551 Phase 4
27 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Not yet recruiting NCT03022617 Phase 4
28 Vascular Inflammation in Psoriasis - Apremilast Not yet recruiting NCT03082729 Phase 4
29 A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Withdrawn NCT01692457 Phase 4
30 Treatment With Apremilast in Patients With Psoriatic Arthritis Withdrawn NCT02558361 Phase 4
31 Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis Completed NCT01087788 Phase 3
32 A Study of Golimumab in Participants With Active Psoriatic Arthritis Completed NCT02181673 Phase 3
33 A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis Completed NCT00051623 Phase 3
34 TIght COntrol of Psoriatic Arthritis Completed NCT01106079 Phase 3
35 A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis Completed NCT01009086 Phase 3
36 A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis Completed NCT00265096 Phase 3
37 Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Completed NCT01925768 Phase 3
38 A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents Completed NCT01077362 Phase 3
39 Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) Completed NCT00235885 Phase 3
40 Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis Completed NCT02024646 Phase 3
41 Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) Completed NCT00367237 Phase 3
42 Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study Completed NCT01877668 Phase 3
43 Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors Completed NCT01882439 Phase 3
44 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01172938 Phase 3
45 Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Completed NCT01392326 Phase 3
46 Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis Completed NCT00195689 Phase 3
47 Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept Completed NCT01901185 Phase 3
48 Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Completed NCT02164214 Phase 3
49 Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis Completed NCT00317499 Phase 3
50 A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) Completed NCT00427362 Phase 3

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: arthritis, psoriatic

Genetic Tests for Psoriatic Arthritis

Genetic tests related to Psoriatic Arthritis:

id Genetic test Affiliating Genes
1 Psoriatic Arthritis, Susceptibility to 29

Anatomical Context for Psoriatic Arthritis

MalaCards organs/tissues related to Psoriatic Arthritis:

39
Skin, Testes, Bone, T Cells, Thyroid, Heart, Endothelial

Publications for Psoriatic Arthritis

Articles related to Psoriatic Arthritis:

(show top 50) (show all 1029)
id Title Authors Year
1
Early recognition and detection of juvenile psoriatic arthritis: a call for a standardized approach to screening. ( 28044348 )
2017
2
Umbilical Plaque in Psoriatic Arthritis. ( 28090061 )
2017
3
Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. ( 28496328 )
2017
4
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. ( 28521047 )
2017
5
Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity? ( 28488125 )
2017
6
Tumor necrosis factor inhibitors in psoriatic arthritis. ( 28490202 )
2017
7
Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. ( 28507445 )
2017
8
Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. ( 28493493 )
2017
9
Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. ( 28483767 )
2017
10
Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis. ( 28507491 )
2017
11
Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: A systematic review. ( 28089501 )
2017
12
Pregnancy Outcomes in Patients with Psoriatic Arthritis. ( 28042130 )
2017
13
Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry. ( 28089969 )
2017
14
ERAP1 and ERAP2 Gene Variations Influence the Risk of Psoriatic Arthritis in Romanian Population. ( 28083616 )
2017
15
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. ( 28473423 )
2017
16
The role of IL-17 in the treatment of psoriatic arthritis. ( 28485176 )
2017
17
Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability. ( 28532452 )
2017
18
Features of some clinical examination parameters in patients with psoriatic arthritis. ( 28511160 )
2017
19
Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis. ( 28527093 )
2017
20
A rare coding allele in IFIH1 is protective for psoriatic arthritis. ( 28501801 )
2017
21
Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. ( 28521824 )
2017
22
New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions. ( 28490011 )
2017
23
Economic impact of biologic utilization patterns in patients with psoriatic arthritis. ( 28474139 )
2017
24
Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. ( 28052860 )
2017
25
Rapid dactylitis resolution in a patient with psoriatic arthritis after treatment with ustekinumab. ( 28073691 )
2017
26
New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: Process and challenges faced. ( 28077693 )
2017
27
Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: Analysis in patients from Central and Eastern Europe. ( 28506134 )
2017
28
Management of psoriatic arthritis (PsA) among cutaneous psoriasis: from pathogenesis to therapy. ( 28534601 )
2017
29
Radiographic scoring instruments have moderate sensitivity but high specificity for detecting change in axial psoriatic arthritis. ( 28085226 )
2017
30
Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine. ( 27586804 )
2016
31
Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. ( 28010883 )
2016
32
Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. ( 28013202 )
2016
33
Associations between five important domains of health and the Patient Acceptable Symptom State in rheumatoid arthritis and psoriatic arthritis: A cross sectional study of 977 patients. ( 27998030 )
2016
34
A national survey on the management of psoriatic arthritis using the Delphi method. ( 27607572 )
2016
35
Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27. ( 26620690 )
2016
36
Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments. ( 27587014 )
2016
37
Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option? ( 27215204 )
2016
38
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). ( 27169431 )
2016
39
Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study. ( 27633825 )
2016
40
Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. ( 27134249 )
2016
41
Interleukin (IL)-9/IL-9R axis drives I^I' T cells activation in psoriatic arthritis patients. ( 27543964 )
2016
42
Risk of cardiovascular morbidity in patients with psoriatic arthritis: A meta-analysis of observational studies. ( 27111228 )
2016
43
Patient-Reported Outcomes in Psoriatic Arthritis. ( 27133489 )
2016
44
Psoriatic arthritis and psoriasis: differential diagnosis. ( 27156076 )
2016
45
Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). ( 27134267 )
2016
46
Initial Experience of Using Dual-Energy CT with an Iodine Overlay Image for Hand Psoriatic Arthritis: Comparison Study with Contrast-enhanced MR Imaging. ( 28045646 )
2016
47
Natural history of isolated nail psoriasis and its role as a risk factor for the development of psoriatic arthritis: a single center cross sectional study. ( 27589338 )
2016
48
Implications of the diversity of class I HLA associations in psoriatic arthritis. ( 27455857 )
2016
49
Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. ( 27527149 )
2016
50
Detection of subclinical ultrasound enthesopathy and nail disease in patients at risk of psoriatic arthritis. ( 27932277 )
2016

Variations for Psoriatic Arthritis

ClinVar genetic disease variations for Psoriatic Arthritis:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TNF TNF, -308G-A single nucleotide variant risk factor
2 LTA NM_001159740.2(LTA): c.-9-198A> G single nucleotide variant risk factor rs909253 GRCh37 Chromosome 6, 31540313: 31540313

Expression for Psoriatic Arthritis

Search GEO for disease gene expression data for Psoriatic Arthritis.

Pathways for Psoriatic Arthritis

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 42)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 CD58 CRP HLA-C HLA-DRB1 IL13 IL1B
2
Show member pathways
13.3 IL13 IL1B LTA PTPN22 TNF TNFRSF1A
3
Show member pathways
13.04 HLA-C HLA-DRB1 IL13 IL1B LTA MMP3
4
Show member pathways
12.88 HLA-C HLA-DRB1 IL13 IL1B LTA MICA
5
Show member pathways
12.81 HLA-C HLA-DRB1 IL13 IL1B LTA TNF
6
Show member pathways
12.79 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B
7
Show member pathways
12.69 IL1B LTA TNF TNFRSF1A TNFRSF1B
8
Show member pathways
12.66 IL1B LTA TNF TNFRSF1A TNFRSF1B
9
Show member pathways
12.6 HLA-DRB1 IL13 IL1B NOD2 TNF
10
Show member pathways
12.5 IL1B LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B
11 12.47 IL1B PTPN22 TNF TNFRSF1A TNFRSF1B TNFSF11
12 12.43 HLA-C HLA-DRB1 LTA TNF TNFRSF1A
13
Show member pathways
12.32 IL13 IL1B MMP3 TNF
14
Show member pathways
12.25 HLA-DRB1 IL1B TNF TNFRSF1A
15 12.25 HLA-DRB1 IL1B NOD2 TNF TNFRSF1A
16
Show member pathways
12.16 HLA-C IL13 IL1B LTA TNF
17 12.12 CD58 HLA-C HLA-DRB1 SELE
18 12.1 IL1B SELE TNF TNFRSF1A
19 12.04 IL1B TNF TNFRSF11B TNFRSF1A TNFSF11
20 11.97 IL13 IL1B MMP3 TNF TNFRSF1B
21 11.87 IL1B LTA TNF TNFRSF1A TNFSF11
22 11.82 IL13 IL1B LTA TNF
23 11.81 HLA-DRB1 IL1B MMP3 TNF TNFSF11
24
Show member pathways
11.77 TNF TNFRSF1A TNFRSF1B TNFSF11
25 11.7 TNF TNFRSF1A TNFRSF1B
26
Show member pathways
11.66 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
27 11.65 IL13 IL1B TNF
28 11.62 LTA TNF TNFRSF1A TNFRSF1B
29
Show member pathways
11.6 IL1B MMP3 SELE TNF TNFRSF1A
30
Show member pathways
11.57 LTA TNF TNFRSF1A TNFRSF1B
31 11.55 COMP IL1B SELE TNF
32 11.48 IL1B TNF TNFRSF11B TNFSF11
33
Show member pathways
11.47 IL1B TNF TNFRSF11B
34
Show member pathways
11.43 TNF TNFRSF1A TNFRSF1B
35 11.41 IL13 IL1B TNF TNFRSF1A TNFRSF1B
36 11.37 IL1B SELE TNF
37 11.32 TNF TNFRSF1A TNFRSF1B
38 11.32 IL13 IL1B TNF
39 11.26 HLA-DRB1 IL13 IL1B TNF
40 11.26 IL1B LTA MMP3 NOD2 SELE TNF
41 11.24 IL13 IL1B LTA TNF TNFSF11
42 11.16 NOD2 TNF TNFRSF1A

GO Terms for Psoriatic Arthritis

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 COMP CRP IL13 IL1B LTA MMP3
2 cell surface GO:0009986 9.7 CD58 HLA-C HLA-DRB1 MICA NOD2 TNF
3 membrane raft GO:0045121 9.62 SELE TNF TNFRSF1A TNFRSF1B
4 extracellular space GO:0005615 9.4 COMP CRP IL13 IL1B LTA MICA
5 plasma membrane GO:0005886 10.07 CD58 HLA-C HLA-DRB1 LTA MICA NOD2

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.98 NOD2 TNFRSF11B TNFRSF1A TNFRSF1B
2 regulation of cell proliferation GO:0042127 9.98 TNF TNFRSF11B TNFRSF1A TNFRSF1B
3 leukocyte migration GO:0050900 9.96 CD58 IL1B SELE TNF
4 defense response GO:0006952 9.88 NOD2 TNF TNFRSF1A TNIP1
5 defense response to bacterium GO:0042742 9.88 MICA NOD2 S100A12 TNF TNFRSF1A
6 response to nutrient GO:0007584 9.86 LTA NOD2 TNFRSF11B
7 cellular response to mechanical stimulus GO:0071260 9.85 IL13 IL1B TNFRSF1A
8 cellular response to organic cyclic compound GO:0071407 9.85 IL1B NOD2 TNF
9 apoptotic signaling pathway GO:0097190 9.85 TNF TNFRSF11B TNFRSF1B
10 regulation of inflammatory response GO:0050727 9.83 NOD2 SELE TNIP1
11 defense response to Gram-positive bacterium GO:0050830 9.83 CRP LTA TNF
12 positive regulation of MAP kinase activity GO:0043406 9.8 S100A12 TNF TNFSF11
13 positive regulation of inflammatory response GO:0050729 9.8 S100A12 TNFRSF1A TNIP1
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 IL1B NOD2 S100A12 TNF TNFSF11
15 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.8 IL1B NOD2 S100A12 TNF TNFRSF1A TNFSF11
16 antigen processing and presentation GO:0019882 9.79 HLA-C HLA-DRB1 MICA
17 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.77 TNF TNFRSF1A TNFRSF1B
18 positive regulation of interferon-gamma production GO:0032729 9.77 IL1B LTA TNF
19 positive regulation of interleukin-6 production GO:0032755 9.76 IL1B NOD2 TNF
20 response to lipopolysaccharide GO:0032496 9.76 IL13 IL1B LTA PTPN22 SELE TNFRSF11B
21 positive regulation of JNK cascade GO:0046330 9.73 IL1B NOD2 TNF TNFSF11
22 tumor necrosis factor-mediated signaling pathway GO:0033209 9.73 LTA TNF TNFRSF11B TNFRSF1A TNFRSF1B TNFSF11
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.7 IL1B PTPN22 TNF
24 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 IL1B TNF
25 positive regulation of interleukin-8 production GO:0032757 9.69 IL1B NOD2 TNF
26 positive regulation of chemokine biosynthetic process GO:0045080 9.67 IL1B TNF
27 negative regulation of lipid storage GO:0010888 9.65 CRP TNF
28 detection of bacterium GO:0016045 9.65 HLA-DRB1 NOD2
29 immune response GO:0006955 9.65 HLA-C HLA-DRB1 IL13 IL1B LTA TNF
30 positive regulation of ceramide biosynthetic process GO:2000304 9.64 TNF TNFRSF1A
31 death-inducing signaling complex assembly GO:0071550 9.64 TNF TNFRSF1A
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IL1B TNF TNFRSF1B
33 cellular response to muramyl dipeptide GO:0071225 9.61 NOD2 PTPN22
34 positive regulation of fever generation GO:0031622 9.61 IL1B TNF
35 sequestering of triglyceride GO:0030730 9.57 IL1B TNF
36 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.56 LTA TNF
37 positive regulation of protein K63-linked ubiquitination GO:1902523 9.55 NOD2 PTPN22
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 IL1B TNF
39 regulation of establishment of endothelial barrier GO:1903140 9.54 IL1B TNF TNFRSF1A
40 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.49 LTA TNF
41 inflammatory response GO:0006954 9.32 CRP IL13 IL1B S100A12 SELE TNF
42 apoptotic process GO:0006915 10.11 COMP IL1B LTA TNFRSF11B TNFRSF1A TNFRSF1B

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.33 LTA TNF TNFSF11
2 tumor necrosis factor-activated receptor activity GO:0005031 9.13 TNFRSF11B TNFRSF1A TNFRSF1B
3 cytokine activity GO:0005125 9.1 IL13 IL1B LTA TNF TNFRSF11B TNFSF11

Sources for Psoriatic Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....